Compare BWEN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWEN | ENGN |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.8M | 117.2M |
| IPO Year | 2009 | N/A |
| Metric | BWEN | ENGN |
|---|---|---|
| Price | $3.91 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $21.08 |
| AVG Volume (30 Days) | 472.0K | ★ 929.4K |
| Earning Date | 05-14-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 360.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,785,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.88 | $1.40 |
| 52 Week High | $5.52 | $12.25 |
| Indicator | BWEN | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.13 | 42.27 |
| Support Level | $1.97 | $1.68 |
| Resistance Level | $5.13 | $1.85 |
| Average True Range (ATR) | 0.53 | 0.10 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 2.40 | 32.00 |
Broadwind Inc is a precision manufacturer of structures, equipment, and components for clean technology and other specialized applications. The company provides technologically high-value products to customers with complex systems and stringent quality standards that operate in the energy, mining, and infrastructure sectors in the United States of America. Its capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treatment, CNG decompression, precision machining, assembly, engineering, and packaging solutions, among others. The company operates in four reportable segments: Heavy Fabrications, which generates the maximum revenue, Gearing, Industrial Solutions, and Corporate.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.